Recurrent Gastric Carcinoma (DBCOND0047958)
Identifiers
- Synonyms
- Gastric carcinoma recurrent / Gastric cancer recurrent / Stomach cancer recurrent / Stomach carcinoma recurrent
Associated Data
- Indicated Drugs and Targets
- Not Available
- Clinical Trials
Identifier Title Drug(s) Purpose Phase Status NCT02465060 Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) - ABSK-091
- Adavosertib
- Afatinib
- Binimetinib
- Capivasertib
- Copanlisib
- Crizotinib
- Dabrafenib
- Dasatinib
- Defactinib
- Erdafitinib
- GSK-2636771
- Ipatasertib
- Larotrectinib
- Methane
- Nivolumab
- Osimertinib
- Palbociclib
- Pertuzumab
- Relatlimab
- Sapanisertib
- Sulfate ion
- Sunitinib
- Taselisib
- Trametinib
- Trastuzumab
- Trastuzumab emtansine
- Tyrosine
- Ulixertinib
- Vismodegib
screening 2 active_not_recruiting NCT03008278 Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery treatment 1 / 2 active_not_recruiting NCT03196232 Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer treatment 2 completed NCT01522820 Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors treatment 1 completed NCT01260701 Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer No drug interventions treatment 2 completed NCT04213794 Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients treatment 0 active_not_recruiting NCT01178944 Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer treatment 2 completed NCT03413397 Lenvatinib Mesylate and Pembrolizumab in Treating Patients With Metastatic or Recurrent Gastric or Gastroesophageal Cancer treatment 2 recruiting